Scandal-Plagued Mylan NV's (MYL) Potential M&A Play

Mylan NV (MYL) is finally making headlines for something other than the EpiPen

Sep 27, 2016 at 10:50 AM
facebook X logo linkedin


While a potential Twitter Inc (NYSE:TWTR) buyout is capturing Wall Street's attention, some other possible acquisitions are brewing elsewhere. In the biotech space, for example, Mylan NV (NASDAQ:MYL) is reportedly mulling a bid for Bayer AG's dermatology business -- ahead of the latter's own merger with Monsanto Company (NYSE:MON).

Specifically, inside sources believe the dermatology unit could be worth upwards of $1.1 billion. And, despite facing extreme scrutiny on Capitol Hill over its EpiPen pricing, MYL could place a bid as soon as this week.

As alluded to, Mylan has been in hot water lately, and that has taken a toll on the drugmaker's stock. Since the EpiPen price-gouging scandal came to light in late August, the shares have dropped nearly 14% -- but were last seen 0.2% higher at $41.27.

Amid this pullback, negative sentiment has been ramping up across the Street. Options traders in the last 10 days have bought to open three times as many MYL puts as calls, based on data from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). The corresponding put/call volume ratio of 2.98 outstrips 86% of all comparable readings from the past year.

Elsewhere, analysts have been lowering their expectations of Mylan NV (NASDAQ:MYL), and two-thirds currently sport tepid "hold" recommendations. Last but not least, short interest on the biotech stock spiked 17.7% during the latest reporting period to over 25 million shares, or 6.5% of MYL's float.

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI